REFERENCES
1. Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol 2019;16:243-56.
2. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13-7.
3. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
4. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
5. Klein LW, Nathan S, Maehara A, et al. SCAI expert consensus statement on management of in-stent restenosis and stent thrombosis. J Soc Cardiovasc Angiogr Interv 2023;2:100971.
6. Farooq V, Serruys PW, Zhang Y, et al. Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. J Am Coll Cardiol 2013;62:2360-9.
7. Secemsky EA, Matteau A, Yeh RW, et al. Comparison of short- and long-term cardiac mortality in early versus late stent thrombosis (from pooled PROTECT trials). Am J Cardiol 2015;115:1678-84.
8. Kristensen SL, Galløe AM, Thuesen L, et al. Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study. PLoS One 2014;9:e113399.
9. Burzotta F, Parma A, Pristipino C, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J 2008;29:3011-21.
10. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
11. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
12. Chau KH, Kirtane AJ, Easterwood RM, et al. Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES. JACC Cardiovasc Interv 2021;14:417-27.
13. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv 2016;9:426-36.
14. Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2018;391:41-50.
15. Tolleson TR, Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003;92:330-3.
16. Costa JR Jr, Sousa A, Moreira AC, et al. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (drug-eluting stents in the real world)-late registry. JACC Cardiovasc Interv 2010;3:12-8.
17. Kubo S, Kadota K, Ichinohe T, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis. Circ J 2014;78:101-9.
18. Navarese EP, Kowalewski M, Kandzari D, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014;1:e000064.
19. Torii S, Cheng Q, Mori H, et al. Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. EuroIntervention 2019;14:1685-93.
20. Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014;7:1081-92.
21. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1043-51.
22. Schochlow K, Weissner M, Blachutzik F, et al. Coronary stent strut fractures: classification, prevalence and clinical associations. J Clin Med 2021;10:1765.
23. Natsuaki M, Watanabe H, Morimoto T, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation 2024;149:585-600.
24. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
25. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
26. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800.
27. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
28. Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 2021;397:1470-83.
29. Moussa ID, Mohananey D, Saucedo J, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol 2020;76:1521-31.
30. Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009;120:1987-95.
31. Pelliccia F, Zimarino M, Niccoli G, et al. In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways. Eur Heart J Open 2023;3:oead083.
32. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
33. Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015;36:2147-59.
34. Adriaenssens T, Joner M, Godschalk TC, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global European effort). Circulation 2017;136:1007-21.
35. Foin N, Lu S, Ng J, et al. Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model. EuroIntervention 2017;13:e1096-8.
36. Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically intermediate coronary stenosis: a single-center trial. JACC Cardiovasc Interv 2020;13:49-58.
37. Nakatani S, Nishino M, Taniike M, et al. Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography. Catheter Cardiovasc Interv 2013;81:776-81.
38. Foin N, Gutiérrez-Chico JL, Nakatani S, et al. Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition. Circ Cardiovasc Interv 2014;7:180-9.
39. Lee JM, Lee SH, Kim J, et al. Ten-year trends in coronary bifurcation percutaneous coronary intervention: prognostic effects of patient and lesion characteristics, devices, and techniques. J Am Heart Assoc 2021;10:e021632.
40. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-66.
41. Qiu F, Mintz GS, Witzenbichler B, et al. Prevalence and clinical impact of tissue protrusion after stent implantation: an ADAPT-DES intravascular ultrasound substudy. JACC Cardiovasc Interv 2016;9:1499-507.
42. Prati F, Romagnoli E, Burzotta F, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC Cardiovasc Imaging 2015;8:1297-305.
43. Ali ZA, Landmesser U, Maehara A, et al. Optical coherence tomography-guided versus angiography-guided PCI. N Engl J Med 2023;389:1466-76.
44. Holm NR, Andreasen LN, Neghabat O, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med 2023;389:1477-87.
45. Zhang J, Gao X, Kan J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial. J Am Coll Cardiol 2018;72:3126-37.
46. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010;50:27-35.
47. Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ. Impact of glycoprotein IIb/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the national cardiovascular data registry. JACC Cardiovasc Interv 2015;8:1574-82.
48. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92.
49. Grimfjärd P, Lagerqvist B, Erlinge D, Varenhorst C, James S. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 2019;5:151-7.
50. Gargiulo G, Esposito G, Avvedimento M, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial. Circulation 2020;142:441-54.
51. Sharifi-Rad J, Sharopov F, Ezzat SM, et al. An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives. High Blood Press Cardiovasc Prev 2023;30:93-107.
52. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3720-826.
53. Sethi A, Bajaj A, Bahekar A, et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction-a meta-regression of randomized controlled trials. Catheter Cardiovasc Interv 2013;82:171-81.
54. Bianchini F, Lombardi M, Ricchiuto A, et al. Combined ultrasound and angiographic guidance to facilitate transradial access procedures. Catheter Cardiovasc Interv 2024;103:443-54.
55. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007;23:57-63.
56. Hahn J, Jeon J, Geum MJ, et al. Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis. Thromb J 2023;21:76.
57. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-26.
58. Mantis C, Kintis K, Papadakis E, Anadiotis A, Patsilinakos S. Glycoprotein IIb/IIIa inhibitors in combination with thrombus aspiration with, or without, stent implantation in patients presenting with S-T elevation myocardial infarction and high thrombus burden. Eur J Cardiovasc Nurs 2021;20:zvab060.021.
59. Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 2012;379:923-31.
60. Prati F, Romagnoli E, Limbruno U, et al. Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: the COCTAIL II trial. Am Heart J 2015;170:1116-23.
61. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
62. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001;21:1094-6.
63. Jiang W, Xiong X, Du X, Ma H, Li W, Cheng F. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Coron Artery Dis 2021;32:25-30.
64. Wang X, Liu H, Wu H, et al. Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden. Coron Artery Dis 2020;31:493-9.
65. Bianchini E, Lombardi M, Buonpane A, et al. Impact of thrombus aspiration on left ventricular remodeling and function in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. Int J Cardiol 2024;397:131590.
66. Jolly SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet 2016;387:127-35.
67. Svilaas T, Vlaar PJ, van der Horst IC. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-67.
68. Jolly SS, James S, Džavík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation 2017;135:143-52.
69. Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013;369:1587-97.
70. De Vita M, Burzotta F, Trani C, et al. Urgent PCI in patients with stent thrombosis: an observational single-center study comparing thrombus aspiration and standard PCI. J Invasive Cardiol 2008;20:161-5.
71. Konstantinou K, Davies JR, Alsanjari O, et al. Clinical effectiveness of thrombus aspiration during percutaneous coronary intervention for stent thrombosis in a contemporary setting. Hellenic J Cardiol 2022;66:11-8.
72. Lemesle G, de Labriolle A, Bonello L, et al. Impact of thrombus aspiration use for the treatment of stent thrombosis on early patient outcomes. J Invasive Cardiol 2009;21:210-4.
73. Mahmoud KD, Vlaar PJ, van den Heuvel FM, Hillege HL, Zijlstra F, de Smet BJL. Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis. Am J Cardiol 2011;108:1721-7.
74. Waldo SW, Armstrong EJ, Yeo KK, et al. Procedural success and long-term outcomes of aspiration thrombectomy for the treatment of stent thrombosis. Catheter Cardiovasc Interv 2013;82:1048-53.
75. Sreenivasan J, Reddy RK, Jamil Y, et al. Intravascular imaging-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials. J Am Heart Assoc 2024;13:e031111.
76. Hill JM, Kereiakes DJ, Shlofmitz RA, et al. Intravascular lithotripsy for treatment of severely calcified coronary artery disease. J Am Coll Cardiol 2020;76:2635-46.
77. Secco GG, Ghione M, Mattesini A, et al. Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon. EuroIntervention 2016;12:359-65.
78. Burzotta F, Bianchini F, Di Giusto F, et al. Long-term outcome of percutaneously managed coronary pseudoaneurysm caused by stent fracture. JACC Cardiovasc Interv 2024;17:315-6.
79. Mishell JM, Vakharia KT, Ports TA, Yeghiazarians Y, Michaels AD. Determination of adequate coronary stent expansion using StentBoost, a novel fluoroscopic image processing technique. Catheter Cardiovasc Interv 2007;69:84-93.
80. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23.
81. Restivo A, Bianchini E, Bellamoli M, et al. Intravascular ultrasound-guided 'OrbiTripsy' for a severely calcified neo-atherosclerotic coronary in-stent restenosis. J Cardiovasc Med 2023;24:931-2.
82. De Maria GL, Scarsini R, Banning AP. Management of calcific coronary artery lesions: is it time to change our interventional therapeutic approach? JACC Cardiovasc Interv 2019;12:1465-78.
83. Merinopoulos I, Gunawardena T, Corballis N, et al. Assessment of paclitaxel drug-coated balloon only angioplasty in STEMI. JACC Cardiovasc Interv 2023;16:771-9.
84. Abdelaziz A, Hafez A, Atta K, et al. Drug-coated balloons versus drug-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention: an updated meta-analysis with trial sequential analysis. BMC Cardiovasc Disord 2023;23:605.
85. Cortese B, Kalkat H, Bathia G, Basavarajaiah S. The evolution and revolution of drug coated balloons in coronary angioplasty: an up-to-date review of literature data. Catheter Cardiovasc Interv 2023;102:1069-77.
86. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J 2020;41:3715-28.
